Fitzroy Dawkins, M.D.– Fitzroy is an independent consultant who transitioned from Forma Thera-peutics in December 2021. He has had more than 16 years of experience leading translational and clinical trials from phase 1 through phase 4 across small and large molecules. Most recently he was the vice president of clinical development at Forma Therapeutics, focused on sickle cell disease and metastatic castrate resistant prostate cancer. Prior to Forma, he was an executive director for Incyte Corporation where he led several teams across multiple targeted molecules- including a PI3Kẟ compound, a JAK1/2 inhibitor, and others. He was the medical lead for a compound that was the first to receive USFDA approval for acute graph versus host disease (GVHD) and ultimate chronic GVHD as well. Prior to Incyte he was a director of clinical development at Janssen Therapeutics where he was the medical lead for a global phase 3 trial in advanced or metastatic ovarian cancer. Overall, he has contributed to the investigation and development of ten compounds while in industry. He has had a passion for enrolling minority patients to clinical trials. Fitzroy earned his Bachelor of Science degree from City University of New York and his M.D. from SUNY, Buffalo. He completed a residency in Internal Medicine in Buffalo, NY. He completed a fellowship in hematology/oncology at George Washington University Medical Center in Washington, D.C. He was then appointed to Howard Uni-versity College of Medicine as Assistant Professor of Medicine. Six years later he was tenured and promoted to Associate Professor, leading the division of hematology/oncology as interim chief.